Piv­otal fail­ure crum­bles stock for Michi­gan’s once-promis­ing Mil­len­do

Even by pan­dem­ic stan­dards, it was a tough Mon­day for Mil­len­do.

The biotech start­up that once grabbed a $62 mil­lion Se­ries B out of Michi­gan …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.